News

Background: Acoramidis is a novel, potent, investigational, transthyretin (TTR) stabilizer under development for the treatment of TTR amyloidosis that results in…

The PAN Foundation helps people living with life-threatening, chronic, and rare diseases with financial help for out-of-pocket treatment costs. Join to learn about…

DUBLIN--(BUSINESS WIRE)--Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics…

The year is flying by and you are invited to a Christmas morning tea in December.The venue, time and place is, as always, set out on the right. I am really looking…

In its native tetrameric form, transthyretin (TTR) protein, which is primarily produced in the liver, serves as a carrier for thyroxin and retinol binding protein […

This study is testing a potential new medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis.The study will look at if this medicine can…

This study will test a medicine, NNC6019-0001, for people who have a heart disease due to TTR amyloidosis. It will look at how safe this medicine is in the long…

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Aug. 30, 2024-- Alnylam Pharmaceuticals, Inc.external link, opens in a new tab (Nasdaq: ALNY), the leading RNAi therapeutics…

In Canada, an active 66-year-old man with no signs or symptoms of heart failure is diagnosed with atrial fibrillation after experiencing several weeks of…